Recent studies have demonstrated that two SIBLING family members,
bone sialoprotein (BSP) and
osteopontin (OPN), are overexpressed in human
prostate cancer. The expression of these
proteins is associated with the acquisition of a metastatic phenotype by
cancer cells and a poor prognosis for the patient.
Dentin sialophosphoprotein (DSPP) shares several structural and genetic features with OPN and BSP. The presence of DSPP has been recently established in salivary glands, indicating that its expression is not restricted to mineralized tissues. However, its potential expression in human
tumors has not been addressed yet. In this study, we sought to evaluate the expression of DSPP in human
prostate cancer. Immunohistochemistry was performed on 69
prostate cancer specimens using LFMb-21 anti-DSPP
monoclonal antibody. All of the
prostate cancer lesions examined expressed detectable levels of DSPP, as compared with no or low level of expression in adjacent normal glands (p < 0.0001). High grade
prostatic intraepithelial neoplasia (HGPIN) glands generally displayed DSPP expression levels that were similar to those found in neighboring
cancer glands. DSPP expression was significantly associated with the pathological stage (p = 0.0087) and the Gleason score (p = 0.0176) of the
tumors. Western Blot was performed on 5 representative prostate
tumor extracts and 3 prostatic tumor cell lines (PC3, LNCaP and DU145). All
tumor extracts and cell lines analyzed have been found to express DSPP. In addition, in situ hybridization was used to assess the presence of DSPP
mRNA. DSPP was detected at the
RNA level in both HGPIN and tumoral glands. This study shows for the first time that DSPP is ectopically expressed in human
prostate cancer. The expression of this SIBLING
protein strongly correlates with conventional histopathological prognostic indicators of
prostate cancer progression.